Long acting GLP-1 receptor agonist (injectable)
Bofanglutide 48 mg injection every 2 weeks
BOFANG_SC_48MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -15.10 (-21.91 to -6.09) | 0.89 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -14.21 (-19.55 to -6.02) | 0.90 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.04 (-6.74 to 8.30) | 0.47 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.15 (0.00 to 2.46) | 0.84 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.75 (4.12 to 20.99) | 0.14 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.65 (3.04 to 15.33) | 0.32 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.19 (0.96 to 4.99) | 0.44 |